Literature DB >> 3523873

A monoclonal anti-C4d that demonstrates a specificity related to anti-Ch.

C M Giles, D S Ford.   

Abstract

A monoclonal anti-C4d reagent, L003, agglutinated untreated and trypsin-treated C4A Rodgers(Rg)- and C4B Chido(Ch)-coated red cells. Inhibition of the agglutination, regardless of the Rg/Ch phenotype of the C4 coat, showed Ch specificity, more precisely, for the Ch1 determinant. C4A allotypes that express Ch1 and Ch3 rather than Rg1 and Rg2, and C4B allotypes that express Rg1 rather than Ch1, Ch2, or Ch3 confirmed that the inhibition specificity in serologic tests was anti-Ch1 and not anti-C4B.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3523873     DOI: 10.1046/j.1537-2995.1986.26486262748.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  5 in total

1.  Effects of C4 null alleles and homoduplications on quantitative expression of C4A and C4B.

Authors:  A Hammond; W Ollier; M J Walport
Journal:  Clin Exp Immunol       Date:  1992-04       Impact factor: 4.330

Review 2.  A structural model for the location of the Rodgers and the Chido antigenic determinants and their correlation with the human complement component C4A/C4B isotypes.

Authors:  C Y Yu; R D Campbell; R R Porter
Journal:  Immunogenetics       Date:  1988       Impact factor: 2.846

3.  Two monoclonal anti-C4d reagents react with epitopes closely related to Rg:1 and Ch:1.

Authors:  C M Giles; A H Fielder; D K Lord; T Robson; G J O'Neill
Journal:  Immunogenetics       Date:  1987       Impact factor: 2.846

4.  Immunoblotting human C4 bound to human erythrocytes in vivo and in vitro.

Authors:  C M Giles; T Robson
Journal:  Clin Exp Immunol       Date:  1991-05       Impact factor: 4.330

5.  The purification and properties of some less common allotypes of the fourth component of human complement.

Authors:  A W Dodds; S K Law; R R Porter
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.